PMS2 and colorectal cancer: Importantly, current international guidelines, including those of the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), recommend the separate immunohistochemical evaluation of MLH1, PMS2, MSH2, and MSH6 in colorectal cancer [36,37].